Clinical-Stage Antibody Therapeutic for Cancer

**OCR Number:** OCR 5478

**Description:**

- Antibodies currently approved for cancer therapy lack the ability to directly penetrate cells.
- OCR 5478 is an **IND-approved** antibody with clinical data for another indication that has been identified as a therapeutic for the treatment of cancer:
  - it is active as a single agent against tumors with deficits in the DNA repair machinery, in particular the BRCA genes
  - it significantly enhances cancer cell sensitivity to DNA-damaging therapies (e.g. radiation therapy, doxorubicin)
- As shown in the figure, a mouse xenograft model using U87 human glioma cells demonstrate that the cell-penetrating antibody synergizes with doxorubicin *in vivo*.

As shown above, a mouse xenograft model using U87 human glioma cells demonstrate that the cell-penetrating antibody synergizes with doxorubicin *in vivo*.

**Stage of Development:** In vivo efficacy studies underway. Further pre-clinical cancer studies planned for this IND-approved antibody.

**IP Status:** Patent application for therapeutic use has been filed.

**Publications:**


[PubMed]
Licensing Contact: John Puziss
john.puziss@yale.edu